Greenyn Biotechnology's Insumate® mcIRBP-19 Bitter Melon Peptide Achieves Triple Certification for Metabolic Health
Key Insights
Greenyn Biotechnology (search)'s Insumate® mcIRBP-19 (search) bitter melon peptide (search) becomes the first globally to receive simultaneous certification from Taiwan Complementary Medicine Society (search), FDA-NDI approval, and SNQ recognition.
Clinical studies demonstrated significant metabolic benefits including 14% reduction in fasting blood glucose and 22% reduction in triglycerides after 12 weeks of treatment.
The patented peptide directly interacts with insulin receptors (search) through unique binding sites, supporting glucose control in a growing global diabetes (search) market projected to reach 853 million cases by 2050.
Greenyn Biotechnology (search) Co., Ltd., a publicly listed biotechnology company in Taiwan, announced that its flagship ingredient Insumate® mcIRBP-19 (search) Bitter Melon Peptide (search) has received "Excellent Product Quality Certification" from the Taiwan Complementary Medicine Society (search) (TCMS). This achievement makes Insumate® the only bitter melon peptide ingredient worldwide to simultaneously hold certification from TCMS, U.S. FDA New Dietary Ingredient (NDI) approval, and Symbol of National Quality (SNQ) recognition.
Addressing Global Metabolic Health Crisis
The certification comes as global diabetes (search) prevalence continues to escalate. According to International Diabetes Federation (IDF) data, 589 million adults worldwide—approximately 1 in 9 people—are living with diabetes as of 2024, with projections indicating this number will reach 853 million by 2050. This growing health burden underscores the critical need for scientifically validated metabolic health solutions.
Decade of Research and Development
Greenyn spent over a decade collaborating with medical schools and biomedical research institutions in Taiwan to develop Insumate®. The company utilized low-temperature supercritical extraction to successfully isolate the bioactive mcIRBP-19 peptide, a precisely sequenced small-molecule peptide extracted from bitter melon. This solvent-free process preserves peptide integrity and bioactivity, distinguishing it from conventional solvent extraction methods that produce undefined polypeptide mixtures.
Clinical Efficacy and Mechanism of Action
Research conducted by Greenyn demonstrates that mcIRBP-19 directly interacts with insulin receptors (search) through a unique binding site, activating downstream signaling pathways that support efficient glucose utilization. Clinical studies in Taiwan showed that consuming mcIRBP-19 for 12 weeks resulted in approximately 14% reduction in fasting blood glucose, over 22% reduction in triglycerides, and significant improvement in HbA1c levels.
For sub-health populations, including aging individuals or those experiencing metabolic slowdown, international studies have shown that high doses of bitter melon components help maintain stable blood glucose levels and significantly improve HbA1c and triglycerides in older subgroups. To date, more than seven SCI-indexed papers and three large-scale clinical trials involving over 200 subjects have validated the ingredient's efficacy.
Professional Recognition and Market Expansion
Dr. Tao-Ming Chen, President of the Taiwan Complementary Medicine Society (search) (TCMS), emphasized that products certified by the organization have met strict standards in scientific validation, clinical evidence, and quality management, offering healthcare professionals a trustworthy reference for supportive nutrition. He noted that while many products claim to contain bitter melon, only patented formulas carrying the Society's certification can truly support daily metabolic management and maintain better overall health.
According to Dr. Pang-Kuei Hsu, Greenyn Biotechnology (search)'s General Manager and R&D lead, this certification confirms that the ingredient has passed stringent reviews covering raw materials, manufacturing, scientific validation, and clinical research, establishing it as a trusted reference for medical professionals selecting nutritional support ingredients.
Global Market Presence
Insumate® has expanded into more than ten countries, achieving commercial launches and demonstrating strong market acceptance across diverse regions. The global nutraceutical market is expected to grow from USD 458.5 billion in 2024 to USD 986.8 billion by 2032, with a compound annual growth rate of 10.18%, according to Fortune Business Insights. The Asia-Pacific region is projected to exceed 30% of global market share by 2026, driven by rising demand for science-backed, clinically effective functional ingredients.
Greenyn continues to strengthen its presence across the Asia-Pacific region and global markets while advancing regulatory pathways across Asia, the U.S., and the EU to support long-term international compliance. The company holds over 100 international patents, more than 30 global invention awards, and maintains certifications under HACCP, ISO 22000, FSSC 22000, and Halal standards.